Anti-inflammatory properties of a novel wound healing and immunomodulating agent, tetrachlorodecaoxygen complex (TCDO).
The first phase of the healing process is characterized by the development of an inflammatory reaction involving migration of inflammatory cells and release of inflammatory mediators. In a previous study, we have demonstrated that the water soluble tetrachlorodecaoxygen complex (TCDO), first synthetized to promote wound healing, inhibits polymorphonuclear (PMN) migration. The aim of the present study was to investigate the activity of TCDO on the progression of an acute non-specific inflammatory reaction, on the release of 6-keto-PGF1 alpha and PGE2 and on PMN oxidative metabolism in the rat. Injected in the pleural cavity, TCDO (15 mumoles/rat) significantly decreased the number of exudative cells while 1.5 mumoles/rat inhibited PMN oxidative metabolism ex vivo (assessed by chemiluminescent assay and measurement of O2- generation) after stimulation of the cells by opsonized zymosan. Similar observations were made in vitro after incubation of PMNs with various concentrations of TCDO (300 to 3 microM). The effect was dose-related and highly significant up to the concentration of 3 microM. In parallel, TCDO decreased the amounts of 6-keto-PGF1 alpha and PGE2 in exudates harvested 1 hour after the intrapleural injection of isologous serum. Effects were significantly different from control levels, from 1.5 to 0.03 mumoles/rat for 6-keto-PGF1 alpha and from 1.5 to 0.01 mumoles/rat for PGE2. This effect was observed when TCDO was injected at the same time or 1 hour before the isologous serum but not later. TCDO also inhibited LTB4 generation in vitro after PMN stimulation by calcium ionophore A23187, at concentrations up to 150 microM. The effects of TCDO in vivo and in vitro on rat PMN functions and inflammatory mediator release mimic certain activities of anti-inflammatory drugs. These properties may be beneficial in the very early stages of the wound healing process.
Tissot
M
M
Départment de Pharmacologie, CNRS URA 595, Hôpital Cochin, Paris.
Roch-Arveiller
M
M
Mathieu
J
J
Giroud
J P
JP
Stahl
K W
KW
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000001:Calcimycin / Q000494:pharmacology; D002713:Chlorine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D015232:Dinoprostone / Q000378:metabolism; D007975:Leukotriene B4 / Q000378:metabolism; D008163:Luminescent Measurements; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction; D010087:Oxides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010994:Pleura; D010998:Pleurisy / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D013481:Superoxides / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010087:Oxides; D013481:Superoxides; D007975:Leukotriene B4; D000001:Calcimycin; D002713:Chlorine; D015121:6-Ketoprostaglandin F1 alpha; C041955:tetrachlorodecaoxide; D015232:Dinoprostone